Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 80 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: maraviroc Clear all
Completed Phase 4 Interventional Results available

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

NCT00735072
View directory record Official record
Conditions
HIV Infection
Interventions
Placebo, Maraviroc
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
San Francisco, California • Stanford, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 2, 2026, 3:47 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women

NCT02333045
View directory record Official record
Conditions
HIV
Interventions
Truvada qd, Maraviroc 300 qd
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 2, 2026, 3:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites

NCT01980329
View directory record Official record
Conditions
Cytochrome P450 CYP3A5 Enzyme Polymorphism, Healthy Subjects, Pharmacokinetics of Maraviroc
Interventions
Maraviroc
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2015 · Synced Sep 2, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available

Expanded Access Program for Maraviroc At Multiple Centers

NCT00426660
View directory record Official record
Conditions
HIV Infections
Interventions
maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
1,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
190
States / cities
Birmingham, Alabama • Hobson City, Alabama • Tucson, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Sep 2, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available

Switch to Maraviroc + Integrase Inhibitor

NCT01896921
View directory record Official record
Conditions
HIV
Interventions
Switch to Maraviroc + Raltegravir or Dolutegravir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 2, 2026, 3:47 AM EDT
Terminated Phase 3 Interventional Results available

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

NCT01345630
View directory record Official record
Conditions
HIV-1
Interventions
Maraviroc, Emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg, placebo for emtricitabine/tenofovir, placebo for maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
84
States / cities
Birmingham, Alabama • Hobson City, Alabama • Hayward, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 2, 2026, 3:47 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

NCT02016924
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 2, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

NCT01400412
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Darunavir, Ritonavir, Tenofovir disoproxil fumarate, Emtricitabine, Placebo for Tenofovir disoproxil fumarate, Placebo for Maraviroc, Maraviroc
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 2, 2026, 3:47 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Trial of CNS-targeted HAART (CIT2)

NCT00624195
View directory record Official record
Conditions
HIV Infections
Interventions
FDA Approved Antiretroviral Therapy (see list below)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
San Diego, California • San Francisco, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 2, 2026, 3:47 AM EDT
Terminated Phase 3 Interventional Results available

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

NCT00440271
View directory record Official record
Conditions
HIV Infections
Interventions
tipranavir, ritonavir, Optimized Background Regimen (OBR)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
16
States / cities
Washington D.C., District of Columbia • Clearwater, Florida • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 2, 2026, 3:47 AM EDT
Completed Phase 1 Interventional

Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)

NCT01133210
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Maraviroc, placebo
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Sep 2, 2026, 3:47 AM EDT
Recruiting Phase 2 Interventional

Antiviral Clinical Trial for Long Covid-19

NCT06511063
View directory record Official record
Conditions
Long Covid
Interventions
tenofovir disoproxil/emtricitabine, Selzentry, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 2, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

NCT01276236
View directory record Official record
Conditions
Kaposi's Sarcoma
Interventions
Maraviroc
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 2, 2026, 3:47 AM EDT
Completed Phase 1 Interventional Results available

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

NCT02858401
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Vesatolimod, Placebo, ARV regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Ft. Pierce, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Sep 2, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

NCT00827112
View directory record Official record
Conditions
Human Immunodeficiency Virus-1
Interventions
maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
27
States / cities
Los Angeles, California • Norwalk, Connecticut • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Sep 2, 2026, 3:47 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

NCT00098722
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc (UK-427,857), optimized background therapy
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
62
States / cities
Hobson City, Alabama • Garden Grove, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Sep 2, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 2, 2026, 3:47 AM EDT
Terminated Phase 4 Interventional

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc

NCT00981318
View directory record Official record
Conditions
HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
lopinavir/ritonavir plus maraviroc
Drug
Lead sponsor
Rodwick, Barry M., M.D.
Individual
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Safety Harbor, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Sep 2, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available

Phase II Maraviroc for GVHD Prevention

NCT01785810
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
Maraviroc 300 mg
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 2, 2026, 3:47 AM EDT
Completed No phase listed Observational

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

NCT00977756
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir (RAL), Atazanavir (ATV), Ritonavir (RTV), Tenofovir (TDF), Etravirine (ETV), Darunavir (DRV), Maraviroc (MVC), Lopinavir/ritonavir (LPV/r)
Drug
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Years to 21 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
33
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Sep 2, 2026, 3:47 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Maraviroc as GVHD Prophylaxis in Transplant Recipients

NCT02167451
View directory record Official record
Conditions
Diagnoses That Require Stem Cell Transplant, Graft Versus Host Disease (GVHD)
Interventions
Maraviroc
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 40 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 2, 2026, 3:47 AM EDT
Not listed Not applicable Interventional

Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

NCT00988780
View directory record Official record
Conditions
Immune Reconstitution Inflammatory Syndrome, HIV, HIV Infections
Interventions
maraviroc, Placebo
Drug
Lead sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Other
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Bethesda, Maryland • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 26, 2012 · Synced Sep 2, 2026, 3:47 AM EDT
Completed Phase 2Phase 3 Interventional

Maraviroc and NeuroAIDS Pathogenesis

NCT02159027
View directory record Official record
Conditions
AIDS Dementia Complex
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 29, 2021 · Synced Sep 2, 2026, 3:47 AM EDT
Completed No phase listed Observational Results available

Prospective Observational Epidemiologic Study of Maraviroc's Safety

NCT00665561
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Maraviroc along with an optimized background antiretroviral drug regimen, Optimized background antiretroviral drug regimen without maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
145
States / cities
Hobson City, Alabama • Huntsville, Alabama • Bakersfield, California + 87 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 2, 2026, 3:47 AM EDT